Last reviewed · How we verify
Tetrandrine Tablets
Tetrandrine is a bisbenzylisoquinoline alkaloid that blocks calcium channels and modulates immune responses, primarily used as an anti-inflammatory and immunosuppressive agent.
Tetrandrine is a bisbenzylisoquinoline alkaloid that blocks calcium channels and modulates immune responses, primarily used as an anti-inflammatory and immunosuppressive agent. Used for Rheumatoid arthritis, Silicosis and pulmonary fibrosis, Autoimmune and inflammatory disorders.
At a glance
| Generic name | Tetrandrine Tablets |
|---|---|
| Sponsor | Peking University Third Hospital |
| Drug class | Calcium channel blocker; immunosuppressive agent |
| Target | L-type and T-type calcium channels |
| Modality | Small molecule |
| Therapeutic area | Immunology; Rheumatology; Pulmonology |
| Phase | FDA-approved |
Mechanism of action
Tetrandrine acts as a non-selective calcium channel antagonist, inhibiting both L-type and T-type calcium channels in various cell types. This mechanism reduces inflammatory mediator release from immune cells and suppresses T-cell proliferation, making it useful in treating autoimmune and inflammatory conditions. It also exhibits antifibrotic properties by inhibiting myofibroblast differentiation and collagen synthesis.
Approved indications
- Rheumatoid arthritis
- Silicosis and pulmonary fibrosis
- Autoimmune and inflammatory disorders
Common side effects
- Gastrointestinal disturbance
- Dizziness
- Headache
- Hypotension
Key clinical trials
- A Study to Test Tetrandrine Tablets for Connective Tissue Disease-Related Lung Disease (PHASE4)
- Tetrandrine Tablets Used in Hospitalized Adults With COVID-19 (PHASE4)
- Tetrandrine Tablets Used in the Treatment of COVID-19 (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tetrandrine Tablets CI brief — competitive landscape report
- Tetrandrine Tablets updates RSS · CI watch RSS
- Peking University Third Hospital portfolio CI